Latham & Watkins Advises SoftBank Vision Fund 2 in Ventus Therapeutics’ US$140 Series C Financing

Ventus Therapeutics, a biopharmaceutical company utilizing structural biology and computational tools to identify and develop small molecule therapeutics across a broad range of disease indications, has announced the closing of a US$140 million Series C financing. The Series C is co-led by SoftBank Vision Fund 2 and RA Capital Management with participation from Qatar Investment Authority, Andreessen Horowitz, BVF Partners L.P., Casdin Capital, Cormorant Asset Management, Fonds de solidarité FTQ, Alexandria Venture Investments, GV (formerly Google Ventures), and founding investor Versant Ventures. 

Latham & Watkins LLP represents SoftBank Vision Fund 2 is the financing with a Bay Area-based emerging companies deal team led by partners Saad Khanani and Ben Potter, with associate Tulin Gurer. Advice was also provided on intellectual property matters by Bay Area partner Jekkie Kim and Los Angeles counsel Jia Jia Huang, with Boston associate Seth Appiah-Opoku.